NOVUS DIAGNOSTICS LIMITED

Novus Diagnostics Limited is a cutting‑edge medical‑technology company dedicated to empowering clinicians with rapid, point‑of‑care diagnostic information. Leveraging patented microfluidic electrochemical sensors and sophisticated diagnostic algorithms, Novus delivers highly accurate bedside results in just 15 minutes, enabling doctors to make confident treatment decisions during the critical early stages of patient triage.

The company’s current focus is on sepsis, a life‑threatening bloodstream infection that claims millions of lives worldwide each year. Novus’s platform not only confirms the presence of infection swiftly but also classifies the causative pathogen as gram‑negative, gram‑positive or fungal, allowing immediate, targeted therapy. This dual capability of rapid infection confirmation and pathogen identification sets Novus apart as a specialist in urgent infectious‑disease diagnostics.

By providing clinicians with timely, reliable data, Novus Diagnostics aims to improve patient outcomes and reduce the mortality associated with delayed treatment, positioning itself as a vital partner for hospitals and healthcare providers seeking next‑generation diagnostic solutions.